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OBJECTIVE— The objective of this study was to describe prevalent vascular retinal lesions
among patients with type 2 diabetes enrolled in the ADVANCE Retinal Measurements (AdRem)
study, a substudy of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) trial.
RESEARCH DESIGN AND METHODS— Seven-field stereoscopic photographs of
both eyes were obtained at the baseline assessment of the ADVANCE trial. All photographs were
graded in a central reading center. Gradable retinal images were received from 1,605 patients.
RESULTS— The number of patients with any retinopathy (Early Treatment of Diabetic Ret-
inopathy Study [ETDRS] score20) was 645 (40.2% [95% CI 37.8–42.6]); of these, 35 (2.2%
[1.6–3.0]) had severe diabetic retinopathy (ETDRS score50). Focal arterial narrowing, venous
beading, and arteriovenous nicking were present in 3.8, 5.1, and 9.8% of participants, respec-
tively. Among participants included in this study, Chinese and South-Asian patients had more
retinopathy than Caucasians, as defined both by ETDRS score (49.4, 46.0, and 31.3%, respec-
tively; P 0.001, adjusted for age, sex, A1C, systolic blood pressure, and duration of diabetes)
and specific vascular lesions (e.g., arteriovenous nicking 12.3, 8.5, and 7.5%, respectively;
adjusted P  0.005). A1C, duration of diabetes, and systolic blood pressure were similarly
associated with increased retinal lesions in Chinese, South-Asian, and Caucasian patients.
CONCLUSIONS— Using a sensitive diagnostic procedure, more than one-third of patients
with type 2 diabetes enrolled in the AdRem study had retinal lesions at baseline. Despite differ-
ences in prevalence and severity of retinopathy among Chinese, South-Asian, and Caucasian
patients included in this study, the cross-
sectional associations among established risk
factors for retinopathy and retinal lesions were
similar across ethnic groups.
Diabetes Care 31:708–713, 2008
D iabetic retinopathy is a progressivedisorder of the microcirculation inthe retina (1). It is the most com-
mon cause of blindness in people aged
30–69 years (2,3). Moreover, the preva-
lence of blindness attributable to diabetic
retinopathy has increased considerably
during recent decades and has doubled in
older people since the 1990s (4). When
not identified and treated early, the dis-
ease is usually progressive, and laser treat-
ment is rarely effective in restoring vision
(5).
From clinical practice it is known that
diabetic retinopathy is the most common
microvascular complication in diabetes,
but most reliable epidemiological data us-
ing fundus photography (including pe-
ripheral retinal fields) cited to support
this notion were obtained from studies
conducted more than a decade ago (6–8).
The management of diabetes and its com-
plications has evolved considerably over
recent years, and these data may no longer
reflect contemporary experience. More-
over, most population-based studies us-
ing fundus photography did not include
patients from Asian countries, where the
prevalence of type 2 diabetes is rising
sharply.
In addition to diabetic retinopathy,
changes in the retinal microcirculation,
such as focal arterial narrowing and arte-
riovenous nicking, are associated with in-
creased risks of stroke, atherosclerosis,
and renal dysfunction (9,10). This find-
ing suggests that retinal vascular lesions
may be important markers of subclinical
vascular diseases. At present there is lim-
ited information on the relationship of
microvascular abnormalities to diabetic
retinopathy and whether this relationship
differs by ethnicity.
Action in Diabetes and Vascular Dis-
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ease: Preterax and Diamicron MR Con-
trolled Evaluation (ADVANCE) is an
ongoing factorial randomized trial of
blood pressure lowering with a fixed low-
dose perindopril-indapamide combina-
tion (versus placebo) and intensive
glucose control with a modified-release
gliclazide-based regimen (versus stan-
dard care) among 11,140 high-risk indi-
viduals with type 2 diabetes from 20
countries in Australasia, Asia, Europe,
and North America (11). As part of the
ADVANCE Retinal Measurements (Ad-
Rem) study, detailed fundus photographs
in a subgroup of ADVANCE participants
were obtained. In this article we present
the prevalence of retinal vascular lesions
in the multiethnic AdRem study popula-
tion at baseline.
RESEARCH DESIGN AND
METHODS— The design of the Ad-
Rem study has been published previously
(12). The main objectives are to deter-
mine the effects of blood pressure lower-
ing and intensive glucose lowering on the
incidence and progression of retinal vas-
cular disorders in patients with type 2
diabetes.
The AdRem study was conducted in
patients that have been randomly as-
signed in the ADVANCE trial in a selected
number of study centers with access to
retinal cameras. Patients were eligible for
the ADVANCE trial if they had their first
diagnosis of type 2 diabetes at age 30
years, were aged 55 years at entry, and
had a high risk of vascular disease as in-
dicated by a diagnosis of diabetes made
10 years before entry, age65 years at
entry, a history of cardiovascular disease
or diabetes complications, or elevated lev-
els of cardiovascular risk factors (11). In
addition to these criteria for inclusion in
the ADVANCE trial, patients who had a
previous ophthalmological intervention
procedure in one or both eyes that might
interfere with retinal circulation (such as
laser coagulation treatment and vitrec-
tomy) were excluded from participation
in the AdRem study.
Assessments of A1C, blood pressure,
smoking, and duration of diabetes were
conducted as part of the ADVANCE Study
(11). Ethnicity was based on self-
categorization derived from question-
naire data. Participants’ ethnicity was
classified as Caucasian/European, Chi-
nese, South Asian/Southeast Asian, and
“other,” which included mainly Arab, Af-
rican, and mixed.
Photography
Photographs were taken with 35-mm
high-quality color films (Kodak EPR64
135-36). Stereoscopic photographs were
made of both left and right eyes, accord-
ing to the seven standard fields Early
Treatment of Diabetic Retinopathy Study
(ETDRS) protocol (13). The seven fields
include one centered on the optic disc,
one centered on the macula, one temporal
to the macula, and two superior and two
inferior fields. In patients with nongrad-
able images according to strict criteria
(12), the centers were asked to obtain re-
peat photographs.
Retinopathy grading
The ETDRS classification was slightly
modified in the United Kingdom Prospec-
tive Diabetes Study (UKPDS), and this
modified classification is used in the Ad-
Rem study (14). Detected lesions were
graded in comparison with the ETDRS fi-
nal scale standard photographs. Vascular
lesions were also assessed in each field
using standard photographs (12).
All images were graded by two inde-
pendent readers. If scores differed a con-
sensus score was assigned by a meeting
with both readers and an experienced
ophthalmologist.
Statistical analyses
Differences in characteristics between pa-
tients with and without retinopathy were
assessed by ANCOVA, with adjustments
for age, sex, A1C, systolic blood pressure,
and duration of diabetes. Use of log-
transformed data did not change the re-
ported associations. Cross-sectional
associations between established risk fac-
tors or ethnicity and the presence of reti-
nal lesions were estimated by multiple
logistic regression analyses. For those risk
factors that showed a significant associa-
tion with retinal disease in the overall
population, these relationships were also
examined in subgroups defined by eth-
nicity. SAS (version 9.1; SAS Institute,
Cary, NC) was used for all analyses.
RESULTS— Retinal images were re-
ceived from 1,984 patients. In the final
analysis, 1,605 (81%) patients had im-
ages of sufficient quality for evaluation.
Patients with nongradable images were
slightly, although significantly, more
likely to be female, more likely to be of
South-Asian ethnicity, were less likely to
be smokers, and were on average older,
with a longer duration of diabetes, higher
levels of A1C, and higher blood pressure
(data not shown).
Table 1 shows clinical characteris-
tics of the participants in the AdRem
study. A total of 645 patients (40.2%
[95% CI 37.8 – 42.6]) had any retinop-
athy (ETDRS score 20). The number
of patients with mild or moderate reti-
nopathy (ETDRS score between 20 and




Female sex (%) 38.6 42.5
Age (years) 65.6  5.8 65.8  6.4




South Asian 11 7.9
Other 3 2
Duration diabetes (years) 7.3  6.1 7.9  6.4
A1C (%) 7.4  1.5 7.5  1.6
Diabetes treatment (%)
Dietician 36 35
Oral glucose-lowering medication 89 91
1 drug 43 43
2 drugs 39 42
3 drugs 7 6
Insulin 1 1
Blood pressure (mmHg) 136/77  21/11 145/81  22/11
Blood pressure lowering medication 70 75
Data are means  SD or %.
Stolk and Associates
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50) was 610 (38.0% [35.6 – 40.4]),
whereas 35 (2.2% [1.6 –3.0]) patients
had severe diabetic retinopathy (ETDRS
score 50). The prevalence of retinop-
athy was not associated with age or sex
(data not shown). Macular edema was
present in 4.1% of men and 3.1% of
women (difference P 0.2). The preva-
lences of specific vascular lesions in this
population were 3.8% with focal arte-
rial narrowing, 5.1% with venous bead-
ing, and 9.8% with arteriovenous
nicking. The presence of each vascular
lesion was strongly associated with the
presence of retinopathy (ETDRS score
20, P  0.001). There were no differ-
ences in the prevalence of any of the
vascular lesions between men and
women.
Table 2 shows that established risk
factors were increased in patients with di-
abetic retinopathy compared with those
without retinopathy. Results were similar
for men and women (data not shown).
The use of oral glucose-lowering drugs or
insulin was not associated with retinopa-
thy. The mean A1C level in patients with
focal arterial narrowing was 0.3% higher
than in patients without focal arterial nar-
rowing (P  0.05), whereas current A1C
levels did not differ significantly in pa-
tients with or without macular edema, ve-
nous beading, and arteriovenous nicking
(data not shown). Systolic and diastolic
blood pressures were higher in patients
with venous beading and macular edema
(P  0.05, adjusted for age, sex, and du-
ration of diabetes). Patients with retinal
vascular lesions had1 year longer dura-
tion of diabetes compared with those
without (P 0.01). Current smoking was
not associated with vascular retinal le-
sions (data not shown).
Almost half of the AdRem population
was of Asian (Chinese or South-Asian)
ethnicity (Table 1). Compared with Cau-
casians, these patients had more retinop-
athy (defined by ETDRS score) and
increased prevalence of vascular lesions
(except focal arterial narrowing) (Table
3). This finding was true for both specific
white- and red-colored lesions (cotton-
wool spots and microaneurysms), which
suggests that misclassification due to their
darker retina is an unlikely explanation.
Patients with Chinese or South-Asian eth-
nicity (mainly Philippine and Malaysian)
were on average younger and had a longer
duration of diabetes, higher A1C levels,
and lower blood pressure levels than
Caucasians (mean SD): 64.9 5.5 ver-
sus 66.5  6.0 years, 8.3  6.4 versus
6.3  5.6 years, 7.6  1.6 versus 7.2 
1.3%, and 135/76  21/11 versus 138/
78  21/10 mmHg, respectively (all P 
0.01). Chinese and South-Asian patients
also, on average, used more glucose-
lowering drugs (53 vs. 38% used two or
more drugs, P  0.01) and more often
received insulin treatment (1.3 vs. 0.5%,
P 0.01) than Caucasians. However, the
differences in prevalence of retinopathy
or vascular lesions among ethnic groups
remained statistically significant after ad-
justment for these variables. The results
were essentially similar after excluding
the minority of patients not living in their
country of origin or including study cen-
ter as an explanatory variable.
The associations among A1C, dura-
tion of diabetes, and systolic blood pres-
Table 2—A1C, duration of diabetes, and blood pressure in patients with and without retinopathy.
Any retinopathy No retinopathy
Retinopathy present
(ETDRS score 20) P value*
n 960 645
A1C (%) 7.2  1.4 7.6  1.6 0.001
Duration of diabetes (years) 6.5  5.7 8.6  6.4 0.001
Systolic blood pressure (mmHg) 135  20 138  21 0.01





(ETDRS score 50) P value*
n 1,570 35
A1C (%) 7.4  1.5 7.8  1.9 0.06
Duration of diabetes (years) 7.3  6.1 8.7  6.4 0.2
Systolic blood pressure (mmHg) 136  21 144  22 0.05
Diastolic blood pressure (mmHg) 77  10 81  13 0.01
Data are means  SD. *Adjusted for age and sex.
Table 3—Prevalence of retinal lesions by ethnicity
Caucasian Chinese South Asian Other P value*
n 770 609 176 50
Retinopathy (ETDRS score 20) 31.3 49.4 46.0 44.0 0.001
Severe retinopathy (ETDRS score 50) 1.2 3.5 1.7 4.0 0.05
Macular edema 2.3 5.4 2.3 10.0 0.001
Focal arterial narrowing 4.2 3.0 4.6 6.0 NS
Venous beading 2.1 8.7 6.3 4.0 0.001
Arteriovenous nicking 7.5 12.3 8.5 18.0 0.005
Data are %. *Adjusted for age, sex, A1C, systolic blood pressure, duration of diabetes, number of glucose-lowering drugs, and insulin use.
AdRem: retinal lesions in type 2 diabetes
710 DIABETES CARE, VOLUME 31, NUMBER 4, APRIL 2008
sure with retinopathy did not differ
significantly by ethnicity (Table 4). After
adjustment for age, sex, and ethnic group,
the odd ratios (ORs) for mild/moderate
retinopathy were 1.24 per percent A1C
(95% CI 1.15–1.33), 1.06 per year of di-
abetes duration (1.04–1.08), and 1.09
per 10 mmHg of systolic blood pressure
(1.03–1.14), respectively (all P 0.001).
Similar associations with severe diabetic
retinopathy and vascular lesions were also
independent of ethnic group. Because of
the small sample size, separate significant
associations within each ethnic group
could not be clearly demonstrated. In all
analyses, interaction terms with ethnic
group were not statistically significant
(P  0.2) except for the OR of diabetes
duration for mild/moderate retinopathy,
which was slightly lower in patients from
China and South Asia compared with
Caucasians (Table 4).
CONCLUSIONS— In this interna-
tional study that included a broad range
of patients with type 2 diabetes, more
than one-third of patients had retinal vas-
cular lesions at baseline diagnosed by a
sensitive procedure. Differences in the
prevalence of these lesions among ethnic
groups were unexplained by differences
in known risk factors for retinopathy.
However, the associations between A1C,
duration of diabetes, and blood pressure
and retinal lesions did not differ signifi-
cantly among ethnic groups.
One of the strengths of the AdRem
study is the use of seven-field stereoscopic
photography of both eyes, allowing the
detection of subtle lesions. This proce-
dure is considered the reference standard
for diagnosing diabetic retinopathy in
randomized clinical trials (15). If smaller
lesions are diagnosed with this approach,
one would expect reporting of a higher
prevalence of retinopathy compared with
studies using single and/or nonmydriatic
cameras. Indeed, the prevalence of reti-
nopathy in the AdRem Study (40.2%) is
higher than that reported in the Multi-
Ethnic Study of Atherosclerosis (MESA)
(33.2%), which is similar to the preva-
lence in previous population-based stud-
ies (16 –19). However, the Diabetic
Retinopathy Candesartan Trial (DI-
RECT), which also used seven-field pho-
tography, reported an even higher
prevalence of retinopathy than the Ad-
Rem study (20).
It has been shown that small vascular
retinal lesions are easily overlooked by di-
rect funduscopy and routine ophthalmo-
logical examination (21). Until now,
vascular measurements have been limited
to 45° photographs centered on the mac-
ula (22). Additional assets of the protocol
used in the AdRem study are the central
film processing and central duplicate
grading of the images. These prevent po-
tential differences in classification among
centers, which is especially relevant when
one is comparing ethnic groups (12).
There are some limitations to the in-
terpretation of these data. The ADVANCE
trial included patients at high risk of vas-
cular disease, which will result in overes-
timation of retinopathy. On the other
hand, exclusion of individuals with pre-
vious laser coagulation treatment would
have resulted in an underestimation of the
prevalence of retinopathy in this popula-
tion. Because we are looking mainly at
mild/moderate retinopathy and vascular
lesions that do not require laser treat-
ment, potential differences in access to
these facilities are unlikely to explain the
differences in prevalence among ethnic
groups. Another limitation of the present
study is its cross-sectional nature, which
limits etiologic inferences from the re-
sults. Therefore, although the cross-
sectional associations described here
are likely to be generalizable, it must be
emphasized that the AdRem study data
are not population-based and hence
the prevalence estimates may not be
representative.
Whereas several studies have com-
pared the prevalence among ethnic
groups within the U.S., the AdRem study
provides the opportunity to directly com-
pare the prevalence of retinopathy and
vascular retinal lesions among different
ethnic groups within their country of
origin. A pooled analysis of studies on di-
abetic retinopathy in the U.S. demon-
strated lower prevalence in Caucasians
compared with Hispanics and blacks
(23). The recent MESA showed that the
prevalence of retinopathy was lower in
white and Chinese diabetic patients com-
pared with Hispanic and black patients
(16). The lower prevalence in Caucasians
is in agreement with our results. The dif-
ference between these results and the Ad-
Rem study findings with respect to
retinopathy prevalence in Chinese pa-
tients may be explained by changes in life-
style associated with migrant populations
and, possibly, earlier diagnosis of diabetes
in the American Chinese population com-
pared with our patients from mainland
China. Differences in recruitment for clin-
ical studies between the U.S. and China
may also play a role. The differences in
risk factors for retinopathy among ethnic
groups are too small to explain the differ-
ences in prevalence of retinopathy in the
AdRem study. Multiethnic studies from
both the U.S., New Zealand, China, and
Hong Kong also show that the ethnic dif-
ferences cannot be explained by differ-
ences in risk factors such as duration of
diabetes, glycemic control, blood pres-
sure, or body weight (16,18,24–26).
Retinal vascular lesions have not been
compared between Asian and Caucasian
populations. However, since vascular le-
sions mirror retinopathy, it is unlikely
that the patterns differ from those re-
ported for retinopathy. Indeed, in the
Atherosclerosis Risk in Communities
(ARIC) study a lower prevalence of vascu-
lar lesions was found in Caucasian than in
black participants (22).
Vascular retinal lesions are common
in patients with diabetes, who also expe-
rience an increased burden of atheroscle-
rotic disease. Follow-up of these patients
will show whether these subtle vascular
lesions are clinically relevant. It is well
known that both increased blood glucose
(or A1C) levels and increased blood pres-
Table 4—Risk factors for mild/moderate retinopathy by ethnicity
Caucasian Chinese South Asian Other
n 770 609 176 50
A1C (per %) 1.23 (1.09–1.38) 1.23 (1.11–1.37) 1.26 (1.03–1.53) 1.18 (0.78–1.79)
Diabetes duration (per year) 1.08 (1.05–1.12) 1.03 (1.01–1.06) 1.02 (0.98–1.07) 1.11 (1.00–1.23)
Systolic blood pressure (per 10 mmHg) 1.05 (0.98–1.13) 1.12 (1.04–1.21) 1.09 (0.92–1.28) 1.20 (0.80–1.80)
Data are ORs, adjusted for age and sex (95% CI).
Stolk and Associates
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sure are risk factors for the incidence and
progression of retinopathy (2,6,27). In
the current cross-sectional study these as-
sociations were confirmed. The differ-
ences in A1C and systolic blood pressure
was of a magnitude similar to that ob-
served in the UKPDS (14).
In the multiethnic studies conducted
in the U.S., the associations between glu-
cose level, diabetes duration, or blood
pressure and the presence of retinopathy
have been reported to be similar across
ethnic groups (16,28). The AdRem study
extends these findings to other ethnic
groups predominantly living in their
country of origin.
In summary, the AdRem study has
shown a high prevalence of retinopathy as
measured by the current “gold standard”
in subjects with diabetes and differing
ethnicity. Follow-up of these patients will
show whether these subtle and peripheral
vascular lesions are clinically relevant.
Despite differences in prevalence and se-
verity of retinopathy among Chinese,
South-Asian, and Caucasian patients, the
cross-sectional associations between reti-
nal lesions and established risk factors for
retinopathy were similar across ethnic
groups. This result suggests that the po-
tential benefits of glucose and blood pres-
sure lowering on diabetic retinopathy will
apply to all people irrespective of ethnic-
ity. The main ADVANCE trial did not
demonstrate clear effects of routine blood
pressure lowering with the perindopril-
indapamide combination on new or
worsening retinopathy (29). However,
the AdRem study provides an opportu-
nity to evaluate the treatment effects using
much more sensitive indicators of retinal
vascular disease progression.
APPENDIX
Members of the AdRem study staff are as
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AdRem Investigators (project team):
Prof. Ronald P. Stolk, Groningen/Utrecht,
the Netherlands (principal investigator);
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J. Aldington, London, U.K.; Prof. Died-
erick E. Grobbee, Utrecht, The Nether-
lands (chair project team); Prof. Alun D.
Hughes, London, U.K.; Prof. Juming Lu,
Beijing, China; Dr. Alice A. Stanton, Dub-
lin, Ireland; Dr. Simon A.McG. Thom,
London, U.K.; and Dr. Johannes R.
Vingerling, Rotterdam, the Netherlands.
Advisors: Prof. Paulus T.V.M. de Jong,
Amsterdam, the Netherlands; Prof. Eva
M. Kohner, London, U.K.
AdRem Coordination Center: Dr. Ronald
P. Stolk (director AdRem Coordination
Center); Truus Meijers (coordinator);
Frank R. Leus (data manager); Dr. Mary J.
van Schooneveld (advisor photo grad-
ing). The AdRem Substudy Coordination
Center is part of the Vascular Imaging
Center of the Julius Center, University
Medical Center Utrecht, the Netherlands:
Karin M. Nijssen (head Vascular Imaging
Center).
ADVANCE Management Committee:
John Chalmers (Chairman) (Australia),
Stephen MacMahon (Vice-Chairman)
(Australia), Mark Cooper (Australia),
Eleuterio Ferrannini (Italy), Paul Glasziou
(Australia), Diederick Grobbee (Nether-
lands), Pavel Hamet (Canada), Stephen
Harrap (Australia), Simon Heller (U.K.),
Liu Lisheng (China), Giuseppe Mancia
(Italy), Michel Marre (France), Carl Mo-
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lia), Chang Yu Pan (China), Anushka
Patel (Australia), Neil Poulter (U.K.), An-
thony Rodgers (New Zealand), Bryan
Williams (U.K.), and Mark Woodward
(Australia).
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